|
Active substance |
Polatuzumab vedotin |
|
Holder |
Roche |
|
Status |
Closed |
|
Indication |
In combination with bendamustine and rituximab for the treatment of adult patients with relapsed/refractory diffuse large B‐cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. |
|
Public documents |
|
|
Last update |
17/09/2021 |
Polivy®
Last updated on 13/09/2024